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Abstract
Background Folate receptor alpha (FR-α) has been identified
as a potential target in ovarian cancer for diagnostic and
therapeutic purposes, based on its overexpression in serous
epithelial ovarian carcinoma. The effect of chemotherapy on
FR-α expression may be important in the applicability of
FR-α directed agents in the case of residual tumor tissue. The
objective of this study was to assess FR-α expression in
ovarian carcinoma and to evaluate whether FR-α expression is
altered by chemotherapy.
Materials & methods FR-α expression was analyzed by
semi-quantitative scoring of immunohistochemical staining
on tissue microarrays (TMAs) from a database containing 361
ovarian cancer tissue samples, of which 210 serous and 116
non-serous carcinoma (35 missing). Serous carcinoma sam-
ples included 28 matched samples with tissue from both
primary surgery and interval debulking surgery, and 12
matched samples with tissue from both primary surgery and
surgery for recurrent disease.
Results FR-α expression was seen in 81.8% of serous
ovarian cancers versus 39.9% of non-serous carcinomas
(p<0.001). In matched serous carcinoma samples, no
significant change in FR-α expression in vital tumor
tissue after chemotherapy was observed (p=0.1). FR-α
expression was not a prognostic marker of progression
free survival (p=0.8) or overall survival (p=0.7).
Conclusion FR-α was expressed in the majority of serous
ovarian tumors, although >50% of cases showed only weak
expression. Chemotherapy did not alter expression rates in
remaining vital tumor tissue, indicating that folate-targeted
agents may have a place in the treatment for ovarian cancer,
before as well as after chemotherapy. Furthermore, FR-α
status did not influence survival.





PFS Progression free survival
1 Introduction
Ovarian cancer is the leading cause of death among
gynaecologic malignancies in the western world [7].
Because of late onset of symptoms, 75% of the patients
are diagnosed with advanced disease. Prognosis in stage III
and IV remains poor with 5-year survival rates of around
30% [18]. Novel approaches to improve survival include
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the development of tumor-targeted diagnostic agents and
drugs. In ovarian cancer, the folate receptor alpha (FR-α)
seems promising for tumor-targeting, as overexpression of
FR-α is seen in 72–97% of serous epithelial ovarian tumors
[8, 12, 14].
Folic acid is used for synthesis of nucleotide bases
and is under physiological conditions taken up by cells
by the reduced folate carrier (RFC) [1]. A second mode
by which folic acid can be internalized, is via the high-
affinity folate receptor (FR), of which the alpha isoform is
overexpressed in ~40% of solid tumors, including ovarian,
renal, lung and breast cancers [14]. Uptake of folate and
folate-conjugates occurs via receptor-mediated endocyto-
sis [9]. Since the macromolecule inside the endosome
remains intact, it can fully exert its function inside the cell
[9, 11]. After endocytosis, the FR is recycled back to the
cell surface where it can again bind circulating folate. The
high affinity of folate for the FR combined with the rapid
recycling of the receptor makes this receptor an attractive
factor for targeted diagnostics and therapy. In the last decade,
several FR-targeted substances have been developed. SPECT-
scanning using the radionuclide 111In-DTPA-folate
showed a strong signal originating from ovarian tumors,
as well as from the kidneys, but no uptake in benign
tumors [13, 15]. Subsequently, interest shifted towards a
99mTc-based folate-tracer because of its shorter half-life
and lower production costs [10]. FR-α targeted chemo-
therapy with farletuzumab (MORAb-003), an antibody
with high affinity for FR-α, is currently under investiga-
tion in the first clinical trials [2, 6, 16]. Furthermore, a
clinical trial is being carried out evaluating the combina-
tion of EC145, an FR-α targeted drug, with Doxil,
compared with Doxil alone for platinum resistant ovarian
cancer (PRECEDENT study; identifier no. NCT00722592;
www.clinicaltrials.gov).
The possibilities for FR-targeted diagnostics and
therapeutics seem promising, but applicability depends
entirely on FR-expression by the target tissue. Chemo-
therapy, either (neo)adjuvant or intraperitoneal, is a vital
part in the treatment for ovarian cancer. Therefore, the
relevance of FR-α targeted agents depends on whether
chemotherapy influences FR-α expression on remaining
vital tumor tissue. Previous studies show that FR-α is
overexpressed on the majority of primary ovarian tumors,
however, the effect of chemotherapy has only been
described once, reporting no significant change in FR-α
expression [8]. To address this question in more detail, we
analyzed FR-α expression in ovarian cancer tumor
samples obtained at primary surgery as well as in samples
obtained directly post-chemotherapy at interval debulking
surgery, and in samples from surgery for recurrent disease.
In addition, we evaluated the impact of FR-α expression
on survival.
2 Materials & methods
2.1 Patient tissue samples
Ovarian cancer specimens were collected from the data-
bank of the University Medical Center Groningen
(UMCG). Since 1985 all clinicopathological and follow-
up data of epithelial ovarian cancer patients treated at the
UMCG are prospectively stored in a database. Tumor
samples from 361 patients were assembled on a tissue
microarray. Borderline and non-epithelial malignancies
were excluded. Treatment for all patients consisted of
Table 1 Patient characteristics
All tumors (n=361)
Age (mean, min-max, SD) 57.5 16–89 SD 13.2
Age; grouped n %
<58 years old 168 46.5
≥58 years old 192 53.2
Missing 1 0.3
Tumor type n %
Serous adenocarcinoma 210 64.4
Other 116 35.6
- Mucinous adenocarcinoma 40 12.3
- Endometrioid adenocarcinoma 51 15.6
- Clear cell carcinoma 22 6.8
- Undifferentiated 3 0.9
Missing 35
FIGO-stage n %
Stage I 70 19.4
Stage II 30 8.3
Stage III 205 56.8
Stage IV 54 15.0
Missing 2 0.6
Grade n %
Grade I 57 15.8
Grade II 96 26.6
Grade III 160 44.3
Undifferentiated 15 4.2
Missing 33 9.1




Size of rest tumor n %
<2 cm 168 46.5
≥2 cm 163 45.2
Missing 30 8.3
Progression free survival (months)
(mean, min-max, SD) 29.6 0–207 SD 36.3
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surgery followed by adjuvant chemotherapy (platinum-
based regimens; since 1995 supplemented by taxanes).
Staging was performed surgically, according to the FIGO
(International Federation of Gynaecology and Obstetrics)
classification [4]. All patient data were anonymized and
all studies concerning this databank were conducted in
accordance with the Declaration of Helsinki principles and
with the rules and regulations posed by the medical ethical
research board (IRB) of the UMCG.
2.2 Sample preparation and immunohistochemistry
For previous studies, tissue microarrays (TMAs) were con-
structed of tumors from 361 patients (de Graeff et al., 2006
[5]), of which 28 matched cases for both primary and interval
debulking surgery, and 12 matched cases for primary surgery
and surgery for recurrent disease. The TMAs contained
control cores consisting of normal ovarian and endometrial
tissue. In order to determine whether these TMAs were
suitable for quantification of FR-α expression, it was
necessary to evaluate the homogeneity of the FR-α staining.
For this purpose, ten randomly selected ovarian tumor
samples were stained for FR-α following the immunohisto-
chemical procedure described below. Uniform staining was
observed throughout tumor tissue in these samples, indicating
the feasibility of using TMAs for further analyses. Renal
tissue, on which FR-α is present under physiologic con-
ditions, was synchronously stained as positive control.
TMAs were cut into 3 μm sections and fixed on coated glass
slides. Sections were deparaffinized with xylene, rehydrated
through a graded series of ethanol and rinsed well in distilled
water. Antigen retrieval was achieved by heating in a high
pressure cooker (Pascal, Dako) in a Target Retrieval Solution
(Dako) for 1 min at 125°C and cooled down to 90°C without
venting of pressure. Slides were cooled down to room
temperature and rinsed with phosphate buffered saline (PBS).
After blocking endogenous peroxidase in 0.3% H2O2 in PBS
for 30 min, sections were incubated with the monoclonal
antibody mAB343 (1.8 mg/ml; a generous gift from prof. P.S.
Low, Endocyte Inc.) in a 1:500 dilution in 1% BSA/PBS
solution for 3 h at room temperature. After washing with PBS,
the sections were incubated with mouse MACH3 (Biocare
Medical). Peroxidase activity was visualized with 3,3-diami-
nobenzidine and slides were counterstained with haematox-
ylin, mounted with mounting medium and coverslipped.
2.3 External validation
In order to validate the staining technique, one TMA (55
samples; 4 cores each) was stained in the laboratory of P.S.
Low. The similar results indicate validity of the staining
protocol.
2.4 Histological analysis
TMAs were graded for FR-α staining using the following
criteria: x = no tumor cells in TMA core or missing core; 0 = no
staining; 1 = weak staining; 2 = moderate staining; 3 = strong
staining according to a previously published study [3]. A
sample was considered positive when at least 25% of the
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tumor cells showed staining. All samples with <2 represen-
tative cores were excluded. First, all cores were judged
separately. Second, one mean score was appointed to each
sample, consisting of four cores. This score was based on the
most frequent staining intensity observed in the sample. For
additional analyses, cases were subdivided in a ‘low staining’
group (score 0 or 1) and in a ‘high staining’ group (score 2 or
3). Scoring was performed, after training, by the primary
researcher (LMAC) and by the pathologist (JB). In case of
different grading, the cores were discussed in a general
meeting until consensus was met.
2.5 Statistical analysis
Descriptive statistics were calculated for variables of interest.
Histology type and FR-α expression were compared using the
chi-square test. Matched samples were compared using the
Wilcoxon signed-rank test. For survival analyses, progression
free survival (PFS) was defined as the time from primary
surgery until progression of the disease or last follow-up.
Disease-specific overall survival (OS) was defined as time
from diagnosis until the last follow-up alive or death due to
ovarian cancer. Survival curves were generated using Kaplan-
Meier analysis. FR-α expression was tested as a prognostic
factor according to a Cox proportional hazards model. All
statistical analyses were carried out using the SPSS 16.0
software package for Windows (SPSS Inc., Chicago, USA).
For all tests, p-values <0.05 were considered statistically
significant.
2.6 Digital microphotography
Microphotographs shown in this paper were acquired
using a Leica DM400B microscope and a Leica DFC320
digital camera (Leica Microsystems GmbH, Wetzlar
Germany).
Negative (0) Weak (1) Moderate (2) Strong (3)
All primary (n=216) 28.2 47.2 19.9 4.7
All interval (n=39) 10.3 43.5 38.5 7.7
All recurrent (n=23) 26.1 34.8 21.7 17.4
Serous primary (n=165) 18.2 53.3 23.0 5.5
Serous interval (n=38) 7.9 44.7 39.5 7.9
Serous recurrent (n=16) 18.8 43.8 25.0 12.5
Other primary (n=51) 60.8 27.5 9.8 2.0
Other interval (n=1) 100.0 0.0 0.0 0.0
Other recurrent (n=7) 42.9 14.3 14.3 28.6
Table 2 FR-α expression
subdivided into histology (top 3
rows, complete cohort; middle 3
rows, serous carcinoma; bottom
3 rows, non-serous carcinoma).
Each group is subdivided into
samples obtained at primary
surgery, at interval debulking
surgery or at surgery for
recurrent disease. Expression
scores are depicted as
percentages
Table 3 FR-α expression in primary tumor samples subdivided into histologic subtype. Non-serous carcinomas are further subdivided; shown in italic
Tumor type N FR-α– FR-α+ Weak (1) Moderate (2) Strong (3)
Serousa 165 30 135 88 38 9
18.2% 81.8% 53.3% 23% 5.5%
All othera 51 31 20 14 5 1
60.8% 39.2% 27.5% 9.8% 2.0%
Mucinous 11 5 6 4 2 0
45.5% 54.5% 36.4% 18.2%
Endometrioid 32 25 7 4 3 0
78.1% 21.9% 12.5% 9.4%
Clear-cell 5 1 4 4 0 0
20% 80% 80%
Undifferentiated 3 0 3 2 0 1
66.7% 33.3%
Missing 35
N; number of cases per group
FR-α–; the number and percentage of samples showing no FR-α expression (negative)
FR-α+; the number and percentage of samples showing FR-α expression. These are further subdivided into weak (1), moderate (2) and strong (3)
expression (right half of table)
a FR-α expression in serous compared to non-serous carcinomas: p<0.001
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3 Results
3.1 Patient characteristics
Baseline characteristics of the 361 patients included in the
database are presented in Table 1.
Of these 361, histology was unknown in 35 cases. Of the
remaining 326 patients, 386 tumor samples were available, of
which 295 obtained during primary surgery, 63 during interval
surgery and 28 during surgery for recurrent disease.
Of the 326 cases with known histology, 210 cases
(64.4%), were serous carcinomas and 116 cases (35.6%)
Primary & postchemo n=28 Primary & recurrent n=12
Age (mean, min-max, SD) 55.1 31–74 SD 9.3 49.8 31–68 SD 12.1
Age; grouped n % n %
< 58 13 46.4 8 66.7
≥ 58 15 53.6 4 33.3
Missing 0 0.0 0 0.0
FIGO n % n %
Stage I 0 0.0 1 8.3
Stage II 1 3.6 2 16.7
Stage III 22 78.6 8 66.7
Stage IV 5 17.9 1 8.3
Grade n % n %
Grade I 3 10.7 2 16.7
Grade II 4 14.3 3 25.0
Grade III 15 53.6 6 50.0
Undifferentiated 2 7.1 0 0.0
Missing 4 14.3 1 8.3
Rest tumor after primary surgery n % n %
Yes 28 100.0 4 33.3
No 0 0.0 7 58.3
Missing 0 0.0 1 8.3
Size of rest tumor n % n %
< 2 cm 1 3.6 7 58.3
≥ 2 cm 25 89.3 2 16.7
Missing 2 7.1 3 25.0
Chemotherapy n % n %
No chemo 0 0.0 1 8.3
Platinum based 14 50.0 8 66.7
Platinum/Taxane 13 46.4 3 25.0
Missing 1 3.6 0 0.0
Progression free survival
(months)
(mean, min-max, SD) 14.7 0–115 SD 21.1 46.6 11–124 SD 36.3
FR-alpha expression (mean, median, SD)
Primary tumor 1.29 1.0 SD 0.897 1.17 1.0 SD 1.03
Interval debulking 1.54 2.0 SD 0.838
Recurrent disease 1.42 1.0 SD 0.793
p=0.1 p=0.5
FR-alpha expression low/high (mean, median, SD)
Primary tumor 0.36 0.0 SD 0.488 0.4 0.0 0.515
Interval debulking 0.52 1.0 SD 0.509
Recurrent disease 0.36 0.0 0.505
p=0.1 p=1.000
Table 4 Patient characteristics
of matched serous carcinoma
samples
Primary & Postchemo (middle col-
umn); cases containing tumor tissue
from both primary surgery and
interval debulking surgery (n=28)
Primary & Recurrent (right col-
umn); cases containing tumor tissue
from both primary surgery and from
surgery for recurrent disease (n=12)
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were of all other histologic subtypes of which mucinous
and endometroid adenocarcinoma were the most prevalent
(12.3 and 15.6%, respectively).
In the group of serous carcinomas, 28 matched cases
contained tumor tissue from both primary and interval
debulking surgery, and 12 cases contained tumor tissue from
both primary and recurrent surgery. Only seven matched cases
for primary and interval debulking surgery could be identified
in the subgroup of non-serous carcinomas.
3.2 FR-α expression
Samples that contained less than two representative cores
were excluded. Representative FR-α scores (Fig. 1) could
Fig. 2 FR-α expression
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be obtained in 278 tumor samples (72%), of which 216
from primary surgery, 39 from interval debulking surgery
and 23 from surgery for recurrent disease. Of the 216
primary tumor samples, 71.8% showed FR-α expression
and 28.2% was negative. Grade was not correlated to FR-α
expression (p=0.4).
An overview of FR-α expression subdivided into histology
is shown in Tables 2 and 3. Of the primary serous
carcinomas, 18.2% was negative; 53.3% showed weak
staining, 23.0% moderate staining and 5.5% strong staining.
Interval debulking tumor samples showed negative expres-
sion in 7.9%, weak staining in 44.7%, moderate staining in
39.5% and strong staining in 7.9%. Recurrent tumors were
negative in 18.8% while 43.8% showed weak staining,
25.0% moderate staining and 12.5% strong staining.
Primary non-serous carcinomas showed no staining in
60.8%, weak staining in 27.5%, moderate staining in 9.8%
and strong staining in 2.0%.
Using the chi square test, a significantly higher staining
was observed in the primary serous carcinomas compared
to non-serous carcinomas (p<0.001).
The combined group of moderate and strong staining
(scores 2–3) showed 28.5% FR-α expression in serous
primary tumors, versus 45.9% (p=0.04) of tumor samples at
interval debulking and 33.3% of recurrent tumors (p=1.000).
All positive controls, consisting of renal tissue, showed
uniform FR-α staining, whereas no staining was observed
on normal ovarian and endometrial tissue cores.
3.3 FR-α expression pre- and postchemotherapy
Twenty-eight cases within the group of serous carcinomas
contained matched samples for both primary and interval
debulking surgery. All patients had received either three or
six cycles of chemotherapy, either platinum-based (50.0%)
or platinum/taxane (46.4%). Nearly all patients had
advanced disease (FIGO stage III–IV; 96.5%). Character-
istics of this subgroup of patients are shown in Table 4.
Fig. 3 Survival curves for serous tumors a—Overall survival (follow-up
in months); p=0.7 b—Progression free survival in months; p=0.8
Table 5 Overall survival and progression free survival in univariate and multivariate analysis (Cox Regression Analysis)
Overall survival Progression free survival Overall survival Progression free survival
Univariate Univariate Multivariate Multviariate
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
All patients with known histology (N=326)
Advanced stage 8.1 4.7–14.1 <0.001 5.9 3.9–8.9 <0.001 4.6 1.8–12.2 0.002 2.8 1.4–5.4 0.003
Age ≥58 years 1.7 1.2–2.2 0.001 1.5 1.1–1.9 0.006 1.1 0.8–1.6 0.5 1.0 0.7–1.4 0.8
Serous type 0.3 0.2–0.5 <0.001 0.3 0.2–0.4 <0.001 1.8 1.1–3.1 0.03 2.0 1.2–3.4 0.008
Residual disease ≥2 cm 4.6 3.3–6.4 <0.001 4.6 3.4–6.4 <0.001 2.3 1.5–3.4 <0.001 2.4 1.6–3.6 <0.001
Grade III/undifferentiated 2.8 2.0–3.9 <0.001 2.7 2.0–3.6 <0.001 0.7 0.5–1.1 0.1 0.8 0.6–1.3 0.008
FR-α overexpression 1.2 0.8–1.7 0.5 1.2 0.8–1.7 0.3 0.8 0.5–1.1 0.2 0.8 0.5–1.2 0.2
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Comparison of staining scores using the Wilcoxon Rank
test showed no difference in FR-α expression (p=0.1) in
remaining vital tumor tissue. Similarly, no significant
difference was found when comparing staining scores
grouped into low expression (score 0 or 1) and high
expression (score 2 or 3) (p=0.1).
Twelve cases contained tissue from both primary and
recurrent disease. All patients underwent three or six cycles
of chemotherapy (Table 4). Comparison of staining scores
showed no significant difference in FR-α expression (p=0.5),
nor in low versus high expression (p=1.000). Staining
patterns pre- and post-chemotherapy are shown in Fig. 2.
When combining scores from interval debulking surgery
and surgery for recurrent disease, 37 cases are matched for
primary and postchemotherapy scores (postchemotherapy
either directly at interval debulking or at surgery for recurrent
disease). Wilcoxon Rank test did not show a difference in
FR-α expression between these groups (p=0.1).
In the group of non-serous carcinomas, only one case
was matched for primary and interval debulking surgery
and four cases were matched for primary and recurrent
disease. These numbers are considered too small to perform
reliable statistical analyses on.
3.4 Survival analysis
As expected, univariate analysis in the cohort of 326
cases of known histology showed that advanced stage,
age ≥58 years of age, residual tumor ≥2 cm, grade III/
undifferentiated and serous histology were associated
with shorter progression free survival (PFS) and
disease-specific overall survival (OS). FR-α expression
(low vs. high), was not associated with PFS or OS. In
multivariate analysis, advanced stage, serous histology
and residual disease were significantly associated with
PFS and OS, whereas age, grade and FR-α expression
were not (Table 5). In the subgroup of serous carcinomas,
advanced stage, residual disease ≥2 cm and high grade
were associated with PFS and OS (data not shown). In the
subgroup of non-serous tumors, univariate analysis
showed associations between stage, age, residual disease
and high grade with OS and between stage, residual
disease and high grade and PFS. Only advanced stage was
prognostic in multivariate analysis (data not shown). The
influence of FR-α expression on PFS and OS is shown in
survival curves (Fig. 3a and b).
4 Discussion
We analyzed FR-α expression in 361 ovarian cancer tissue
samples, of which 326 with known histology. We showed
FR-α expression in 81.8% of serous carcinomas, versus
39.2% in non-serous carcinomas (p<0.001). FR-α expres-
sion did not change significantly after chemotherapy,
neither in vital tumor tissue obtained during interval
debulking surgery (p=0.1) nor in tumor tissue obtained
during surgery for recurrent ovarian cancer (p=0.5).
Table 6 Studies reporting FR-α expression in ovarian cancer
Study No. of patients Method FR-α expression
Toffoli (1997)[17] 136 Cytofluorimetric 89.7%




Bagnoli (2003)[3] 168 Immunohistochemistry 85.1% non-mucinousa









Markert (2008)[12] 104 Immunohistochemistry 97% non-mucinousc
a Serous, endometrioid and clear-cell carcinoma
bOf 14 mucinous tumors, 36% showed only weak FR-α expression
c Serous (n=8), serous-papillary (n=79) and papillary carcinoma (n=17)
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Furthermore, FR-α expression in primary ovarian tumors
was not associated with survival.
Several studies, summarized in Table 6, report FR-α
expression in smaller patient cohorts.
Toffoli et al. reported overall expression of the folate
binding protein (FBP) in 89.7% of 136 patients, with a
significant difference in expression between serous and
mucinous tumors. FR-α expression was determined using
cytofluorimetric analysis [17]. Wu et al. described FR-α
expression in gynaecologic malignancies (n=23), measured
with in situ hybridization histochemistry. Of 23 malignant
ovarian samples, 100% FR-α expression was seen in serous
and endometrioid carcinoma (n=15), versus 0% expression in
mucinous and clear-cell carcinoma (n=8) [19]. Bagnoli et al.
analyzed 168 non-mucinous ovarian malignancies, in which
an expression rate of 85.1% was found [3]. Parker et al.
compare expression rates in animal tissues and human tissues.
Of 29 ovarian tumor patient samples, 100% expression rates
were seen in serous and endometrioid carcinoma and
metastatic tissue. Only weak expression was seen in 36% of
mucinous carcinoma [14]. Kalli et al. reported overall
expression in 72% of primary ovarian tumors (n=186), with
higher expression in serous carcinoma (81.7%) than in other
histologic subtypes (59.8%), with lowest expression in
mucinous tumors (22.2%) [8]. Markert et al. reported 97%
expression in a series of 104 malignant ovarian tumors, but
did not specify percentages for histologic subtype [12].
When comparing our data to these studies, FR-α
expression in serous carcinoma appears comparable. Re-
markable is the high expression rate reported by Markert et
al. All studies are uniform in showing low expression rates
in mucinous carcinoma, as do we.
The study by Kalli et al. is the only to report FR-α
expression in 24 matched samples of both primary and
recurrent tumors. No significant difference in expression
was found [8]. Our data support these findings. Moreover,
by comparing primary surgery specimens to samples from
interval debulking surgery as well as to recurrent tumors,
we show that chemotherapy has neither a direct, nor a late
effect on FR-α expression in remaining vital tumor tissue.
Although our data are in general in line with the reported
literature, a remarkable finding is the weak FR-α expression
in the majority (53.3%) of the primary serous carcinomas. We
observed ‘moderate’ or ‘strong’ staining in only 28.5%.
Numbers are slightly higher in interval debulking specimens
and recurrent tumors, but do not exceed 50%. Little is known
regarding the required intensity of FR-α expression for
clinical application. Theoretically, lower expression rates
may negatively influence the effectiveness of folate-based
compounds. Since no data are available to confirm whether
low expression implicates less effective tumor-targeting,
further studies are warranted to elucidate this question. From
the present study, we conclude that the strength of FR-α
expression may be a relevant factor to be specifically
addressed in future studies.
In summary, this study confirms previously found FR-α
expression rates of ~82% in serous ovarian carcinoma,
although strong expression was seen in a smaller proportion
of tumors than earlier reported. FR-α was not associated
with progression free survival, nor with disease-specific
overall survival. Furthermore, in this limited series, we
show that chemotherapy does not significantly alter FR-α
expression in vital residual tumor tissue, thus strengthening
the rationale for FR-α targeted diagnostic agents and drugs.
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